Clinical Trials Sponsored by Elgene Chemical

Total 2110 results

Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Celgene

Completed

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Renal Insufficiency

United States
Celgene

Available

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Multiple Myeloma
Celgene

Completed

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Diffuse Large B-Cell Lymphoma | Multiple Myeloma | Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Glioblastoma Multiforme | Neuroendocrine Tumors of Non-Pancreatic Origin | Hormone Receptor-Positive Breast Cancer

United States, Spain, United Kingdom, France
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.

Healthy Volunteers

United States
Celgene

Completed

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) (PASS MDS del5q)

Myelodysplastic Syndrome

Spain, United Kingdom, Denmark, Germany, France, Greece, Italy, Sweden, Belgium, United States, Luxembourg, Norway
Celgene

Completed

Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma (PrObe-L)

Multiple Myeloma

Portugal
Celgene

Completed

A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan
Celgene

Completed

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

Healthy Volunteers

United States
Celgene

Completed

A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene

Completed

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Multiple Myeloma

Austria, Italy, France, Spain, Netherlands, Germany, Greece, United Kingdom
Celgene

Completed

A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677

Healthy Volunteer

United Kingdom
Celgene

Completed

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Hematologic Neoplasms

Spain, United States
Celgene

Completed

A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

United States, Spain, Italy, France
Celgene

Completed

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Diffuse B-Cell Lymphoma

Canada, Spain, Belgium, United States
Celgene

Completed

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (RADIANCE)

Relapsing Multiple Sclerosis

Spain, United States, United Kingdom, Croatia, Serbia, Belarus, Hungary, Bulgaria, Poland, Italy, Ukraine, Greece, Belgium, Georgia, Bosnia and Herzegovina, Moldova, Republic of, Romania, Russian Federation, Slovakia, South Africa and more
Celgene

Completed

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Poland, Ukraine, Hungary, Canada
Celgene

Completed

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States
Celgene

No longer available

Expanded Access for ACE-011

Myelodysplastic Syndrome

United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

Psoriasis

United States, Canada
Celgene

Completed

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

Colorectal Neoplasms

France
Celgene

Completed

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

United States
Celgene

Completed

A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

Sarcoidosis, Pulmonary

United States, United Kingdom, Netherlands
Celgene

Completed

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

United States, Spain, Germany, France, Czechia, Australia, Sweden, United Kingdom, Ukraine, Poland
Celgene

Completed

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Melanoma | Sarcoma, Soft Tissue | Cancer | Fibrosarcoma | Neuroblastoma | Osteogenic Sarcoma | Rhabdomyosarcoma | Neoplasm | Malignant Melanoma | Tumors | Histiocytoma | Dermatofibrosarcoma | Sarcoma, Ewing's | Neoplasia | Ewing's Sarcoma | Ewing's Tumor | Sarcomas, Epitheliod | Sarcoma, Spindle Cell | Clinical Oncology | Oncology,... and other conditions

United States, Canada, Spain, France, United Kingdom, Italy, Switzerland
Celgene

Completed

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Taiwan
Celgene

Completed

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Hematologic Malignancy | Malignant Lymphoma

United States, United Kingdom
Celgene

Terminated

Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

Hemodialysis Graft Dysfunction

United States
Celgene

Completed

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

United States, Australia, Italy, Spain, France, Austria, Sweden, Czechia, United Kingdom
Celgene

Terminated

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Breast Neoplasms | Neoplasm Metastasis

United States, Puerto Rico
Celgene

Completed

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

Hormone Refractory Prostate Cancer

United States
Celgene

Completed

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function (RENAL)

Multiple Myeloma | Non-Hodgkin's Lymphoma | AML | Solid Tumors | MDS | Hodgkin's Disease

United States
Celgene

Terminated

A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). (RENEW)

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

United States, Spain, United Kingdom, Germany, France, Czechia, Israel, Italy, Poland, Portugal, Puerto Rico, Russian Federation
Celgene

Completed

Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

Myelodysplastic Syndromes

Japan
Celgene

Terminated

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Carcinoma, Small Cell

United States, Canada
Celgene

Completed

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer

Belgium, United Kingdom, Netherlands, Italy, Poland
Celgene

Completed

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Myelodysplastic Syndromes

United States, Germany
Celgene

Terminated

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Fibrosis | Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung Diseases, Interstitial | Interstitial Lung Disease

United States, Canada
Celgene

Completed

Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies (GAH)

Myelodysplastic Syndromes | Multiple Myeloma | Leukemia Myeloid Acute | Leuklemia, Lymphocytic, Chronic

Spain
Celgene

Completed

A Safety Study of ABI-007 for In-Stent Restenosis

Coronary Artery Disease | Angina Pectoris

United States
Celgene

Completed

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma (OPTIMUM)

Multiple Myeloma

India, Philippines, France, Portugal, Poland, South Africa, Bulgaria, Croatia, Czechia, Germany, Hungary, Italy, Serbia, Slovakia, United Kingdom
Celgene

Approved for marketing

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma (PEXIUS)

Multiple Myeloma

United States, Canada
Celgene

Completed

Radiolabeled Study of CC-122 in Healthy Subjects

Healthy Volunteers

United States
Celgene

Completed

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Japan
Celgene

Completed

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Healthy

United States
Celgene

Completed

CC-223 and Ketoconazole Drug-Drug Interaction Study

Healthy Volunteers
Celgene

Completed

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer

United States, Spain
Celgene

Completed

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

Multiple Myeloma

China

3

Subscribe